• Publications
  • Influence
Mutational landscape and clonal architecture in grade II and III gliomas
Mutations showed significant positive and negative correlations and a chronological hierarchy, as inferred from different allelic burdens among coexisting mutations, suggesting that there is functional interplay between the mutations that drive clonal selection. Expand
Current Trends in Targeted Therapies for Glioblastoma Multiforme
Up-to-date clinical trials of GBM treatments are reviewed to aim at more therapeutical effect than conventional therapies that are ongoing or are about to launch in clinical settings and discuss future perspectives. Expand
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Gefitinib appears to be effective in treating brain metastases in a subgroup of patients and a possible association between the efficacy of gefit inib in the treatment of brain metastase and EGFR mutations is suggested. Expand
Lack of presence of the human cytomegalovirus in human glioblastoma
HCMV is not persistent, at least in the tumor cells, of developed human glioblastoma, as the QPCR analysis could detect 10 copies of HCMV DNA mixed with DNA extracted from 104 H CMV-negative cells. Expand
Novel somatic and germline mutations in intracranial germ cell tumours
A molecular foundation for understanding the biology of IGCTs is established and potentially promising therapeutic strategies focusing on the inhibition of KIT/RAS activation and the AKT1/mTOR pathway are suggested. Expand
Benefits of interferon‐β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter
The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigeneticExpand
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
It is shown that IFN-beta sensitizes glioma cells that harbor the unmethylated MGMT promoter and are resistant to temozolomide, and it is revealed that the sensitizing effect of IFn-beta was possibly due to attenuation of MGMT expression via induction of the protein p53. Expand
Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas.
The global epigenome analysis reveals distinct patterns of methylation that are probably to represent different pathophysiologic processes in HCCs, and methylation in the Type IV genes is characteristic of moderately/poorly differentiated cancer. Expand
The DNA demethylating agent 5‐aza‐2′‐deoxycytidine activates NY‐ESO‐1 antigenicity in orthotopic human glioma
Microarray analysis revealed that 5‐aza‐CdR is capable of signaling the immune system, particularly, human leukocyte antigen (HLA) class I upregulation, and systemic administration of 5-aza‐ CdR resulted in a significant volume reduction of the transplanted tumors and prolonged the survival of the animals after the adoptive transfer of NY‐ESO‐1‐specific CTLs. Expand
Glioma-initiating cells and molecular pathology: implications for therapy
Some of the signaling mechanisms involved in GIC biology, such as phosphatase and tensin homolog (PTEN), sonic hedgehog, Notch, and WNT signaling pathways, maternal embryonic leucine-zipper kinase (MELK), BMI1, and Janus kinase signal transducer and activator of transcription (JAK-STAT) signaling are reviewed. Expand